Skip to main content

Table 4 Statistical relationship between the NCS and other variables

From: Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer

Variables

NCS

p

0 n (%)

1 n (%)

2 n (%)

Sex

0.585

 Female

44 (26.19%)

51 (29.14%)

19 (23.17%)

 Male

124 (73.81%)

124 (70.86%)

63 (76.83%)

Age

<0.001

 <65years

106 (63.10%)

85 (48.57%)

25 (30.49%)

 ≥65years

62 (36.90%)

90 (51.43%)

57 (69.51%)

Tumor size

0.001

 <5cm

120 (71.43%)

97 (55.43%)

40 (48.78%)

 ≥5cm

48 (28.57%)

78 (44.57%)

42 (51.22%)

Differentiation

0.252

 Moderate/well

100 (9.52%)

101 (57.71%)

40 (48.78%)

 Poor

68 (40.48%)

74 (42.29%)

42 (51.22%)

Borrmann type

0.001

 I–II

109 (64.88%)

87 (49.71%)

34 (41.46%)

 III–IV

59 (35.12%)

88 (50.29%)

48 (58.54%)

Tumor depth

<0.001

 T1

35 (20.83%)

10 (5.71%)

0 (0)

 T2

30 (17.86%)

15 (8.57%)

2 (2.44%)

 T3

90 (53.57%)

100 (57.14%)

40 (48.78%)

 T4

13 (7.74%)

50 (28.57%)

40 (48.78%)

Lymph node

<0.001

 N0

70 (41.67%)

24 (13.71%)

6 (7.32%)

 N1

63 (37.50%)

81 (46.29%)

37 (45.12%)

 N2

30 (17.86%)

48 (27.43%)

25 (30.49%)

 N3

5 (2.98%)

22 (12.57%)

14 (17.07%)

Distant metastasis

<0.001

 M0

166 (98.81%)

157 (89.71%)

70 (85.37%)

 M1

2 (1.19%)

18 (10.29%)

12 (14.63%)

pTNM stage

<0.001

 I

53 (31.55%)

14 (8.00%)

1 (1.22%)

 II

75 (44.64%)

69 (39.43%)

18 (21.95%)

 III

38 (22.62%)

74 (42.29%)

51 (62.20%)

 IV

2 (1.19%)

18 (10.29%)

12 (14.63%)

CEA

<0.001

 ≤5ng/ml

130 (77.38%)

117 (66.86%)

29 (35.37%)

 >5ng/ml

38 (22.62%)

58 (33.14%)

53 (64.63%)

PLR

<0.001

 ≤127.8

112 (66.67%)

62 (35.43%)

20 (24.39%)

 >127.8

56 (33.33%)

113 (64.57%)

62 (75.61%)

LMR

<0.001

 ≤4.93

52 (30.95%)

114 (65.14%)

71 (86.59%)

 >4.93

116 (69.05%)

61 (34.86%)

11 (13.41%)

  1. (1) PLR the platelet-to-lymphocyte ratio, LMR the lymphocyte-to-monocyte ratio. (2) NCS the NLR-CA19-9 score